TRDA (Entrada Therapeutics, Inc.) Stock Market Reviews

crown

search

Read and share opinions on TRDA (Entrada Therapeutics, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock mark

TRDA

Entrada Therapeutics, Inc.

clarify Biotechnology

bookmark Healthcare

public United States

Sell Neutral Buy

Latest News

Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Misses Revenue Estimates
Nov 6, 2025
Entrada Therapeutics to Present at Upcoming Investor Conferences
Oct 28, 2025
Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program
Sep 5, 2025
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 2, 2025
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Aug 9, 2025
Entrada Therapeutics Second Quarter 2025 Earnings: Misses Expectations
Aug 7, 2025
Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Lags Revenue Estimates
Aug 6, 2025
Entrada Therapeutics (TRDA) Soars 5.6%: Is Further Upside Left in the Stock?
Jul 31, 2025
Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
Jun 3, 2025
Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
May 28, 2025
Analysts Are Upgrading Entrada Therapeutics, Inc. (NASDAQ:TRDA) After Its Latest Results
May 11, 2025
Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue Estimates
May 8, 2025
Analysts Estimate Entrada Therapeutics, Inc. (TRDA) to Report a Decline in Earnings: What to Look Out for
Apr 29, 2025

Reviews